Next Article in Journal
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future
Next Article in Special Issue
Renal Cell Carcinoma: A Study through NMR-Based Metabolomics Combined with Transcriptomics
Previous Article in Journal
New Tools for Molecular Therapy of Hepatocellular Carcinoma
Previous Article in Special Issue
Metabolomic Approaches in Cancer Epidemiology
Article Menu

Export Article

Open AccessReview
Diseases 2015, 3(4), 341-359; doi:10.3390/diseases3040341

An Integrated Outlook on the Metagenome and Metabolome of Intestinal Diseases

1,†
and
1,2,†,*
1
Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata 997-0052, Japan
2
RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Liang Zhao
Received: 1 September 2015 / Revised: 30 October 2015 / Accepted: 2 November 2015 / Published: 6 November 2015
(This article belongs to the Special Issue Advances and Applications of Metabolomics in Human Diseases)
View Full-Text   |   Download PDF [1399 KB, uploaded 9 November 2015]   |  

Abstract

Recently, metagenomics and metabolomics are the two most rapidly advancing “omics” technologies. Metagenomics seeks to characterize the composition of microbial communities, their operations, and their dynamically co-evolving relationships with the habitats they occupy, whereas metabolomics studies unique chemical endpoints (metabolites) that specific cellular processes leave behind. Remarkable progress in DNA sequencing and mass spectrometry technologies has enabled the comprehensive collection of information on the gut microbiome and its metabolome in order to assess the influence of the gut microbiota on host physiology on a whole-systems level. Our gut microbiota, which consists of prokaryotic cells together with its metabolites, creates a unique gut ecosystem together with the host eukaryotic cells. In this review, we will highlight the detailed relationships between gut microbiota and its metabolites on host health and the pathogenesis of various intestinal diseases such as inflammatory bowel disease and colorectal cancer. Therapeutic interventions such as probiotic and prebiotic administrations and fecal microbiota transplantations will also be discussed. We would like to promote this unique biology-wide approach of incorporating metagenome and metabolome information as we believe that this can help us understand the intricate interplay between gut microbiota and host metabolism to a greater extent. This novel integration of microbiome, metatranscriptome, and metabolome information will help us have an improved holistic understanding of the complex mammalian superorganism, thereby allowing us to gain new and unprecedented insights to providing exciting novel therapeutic approaches for optimal intestinal health. View Full-Text
Keywords: gut microbiota; luminal metabolites; colorectal cancer; inflammatory bowel disease; metabolomics; metagenomics gut microbiota; luminal metabolites; colorectal cancer; inflammatory bowel disease; metabolomics; metagenomics
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Aw, W.; Fukuda, S. An Integrated Outlook on the Metagenome and Metabolome of Intestinal Diseases. Diseases 2015, 3, 341-359.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top